<DOC>
	<DOCNO>NCT00115960</DOCNO>
	<brief_summary>The purpose study determine safety immune response experimental HIV vaccine , HIV-1 gag DNA , without IL-15 DNA adjuvant ( escalate dose 100 , 500 , 1500 mcg ) . This study also test safety immune response HIV-1 gag DNA vaccine plus IL-15 DNA adjuvant give without 2 adjuvant-containing booster vaccine .</brief_summary>
	<brief_title>Safety Immune Response HIV Preventive Vaccine ( HIV-1 Gag DNA Alone With IL-15 DNA ) Given With Without 2 Different Booster Vaccinations HIV Uninfected Adults</brief_title>
	<detailed_description>The HIV epidemic major global health challenge , cause tremendous human suffer economic loss throughout world . The need safe , effective , affordable HIV preventive vaccine critical . This 2-part study determine safety immunogenicity experimental HIV vaccine HIV-1 gag DNA without IL-15 adjuvant , boost either HIV-1 gag DNA IL-15 adjuvant vaccine HIV-1 gag DNA IL-12 adjuvant vaccine . There two part study . Part A last 12 month . In Part A , 48 participant randomly assign 1 4 group sequential order ( dose escalation ) . All participant receive 3 vaccination . Group 1 receive 3 vaccination HIV-1 gag DNA vaccine placebo . Group 2 receive 3 vaccination either HIV-1 gag DNA vaccine low dose IL-15 adjuvant placebo . Group 3 receive 3 vaccination either HIV-1 gag vaccine medium dose IL-15 adjuvant placebo . Group 4 receive 3 vaccination either HIV-1 gag vaccine high dose IL-15 adjuvant placebo . Vaccinations give Months 0 , 1 , 3 . There 11 study visit Part A . A physical exam , pregnancy prevention counseling , medication history , adverse event reporting occur visit . Urine blood collection occur visit . Participants also ask complete questionnaire certain visit . Part B last 15 month . In Part B , 72 participant randomly assign 1 2 group . All Part B participant receive 5 vaccination . Group 5 receive 5 vaccination either HIV-1 gag vaccine plus IL-15 DNA placebo ; vaccination occur Months 0 , 1 , 3 , 6 , 9 . Group 7 receive 3 vaccination HIV-1 gag vaccine high dose IL-15 adjuvant ( maximum tolerate dose Part A ) follow 2 vaccination gag DNA vaccine IL-12 DNA adjuvant . Some participant receive placebo instead vaccine regimen . For Group 7 , HIV-1 gag vaccine IL-15 adjuvant vaccination give Months 0 , 1 , 3 , booster vaccination give Months 6 9 . There 13 study visit Part B . A physical exam , pregnancy prevention counseling , medication history , adverse event reporting occur visit . Urine blood collection occur visit . Participants also ask complete questionnaire certain visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>Note : Group 6 remove Part B protocol 04/11/06 amendment . Because regimen similar Group 6 's regimen test HVTN 060 , vaccine manufacturer decide Group 6 's regimen priority test . HIV uninfected Access participate HIV Vaccine Trials Unit ( HVTU ) Willing receive HIV test result Willing able comply study requirement In good general health Willing use acceptable method contraception least 21 day prior study entry last study visit . More information criterion find protocol . Hepatitis B surface antigen negative Antihepatitis C virus ( antiHCV ) antibody negative negative HCV PCR antiHCV antibody positive HIV vaccine prior HIV vaccine trial Immunosuppressive medication within 168 day prior first vaccination Blood product within 120 day prior first vaccination Immunoglobulin within 60 day prior first vaccination Live attenuate vaccine within 30 day prior first vaccination Investigational research agent within 30 day prior first vaccination Medically indicate subunit kill vaccine within 14 day prior first study vaccine administration , allergy treatment antigen injection within 30 day prior first vaccination Current tuberculosis ( TB ) prophylaxis therapy Clinically significant medical condition , physical exam finding , abnormal laboratory result , past medical history clinically significant implication current health Any medical , psychiatric , social condition , opinion investigator , may interfere study Any occupational responsibility , opinion investigator , may interfere study Diagnosis allergy amidetype local anesthetic Serious adverse reaction vaccine , include anaphylaxis relate symptom hive , respiratory difficulty , angioedema , abdominal pain . A person adverse reaction pertussis vaccine child exclude . Autoimmune disease immunodeficiency Unstable asthma Diabetes mellitus Type 1 Type 2 . Participants history isolate gestational diabetes exclude . Thyroid disease require treatment past 12 month Serious angioedema within last 3 year Uncontrolled hypertension Body mass index ( BMI ) 40 great OR BMI 35 great , certain criterion meet . More information criterion find protocol . Bleeding disorder Cancer . Participants surgically remove cancer , opinion investigator , unlikely recur exclude . Seizure disorder require medication within past 3 year Absence spleen Psychiatric condition , include psychosis within past 3 year , ongoing risk suicide , history suicide attempt gesture within past 3 year Pregnant breastfeeding , plan become pregnant study Exclusion Criteria Part B Participants : Diagnosis allergy egg product Diagnosis allergy yeastderived product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>IL-12</keyword>
	<keyword>IL-15</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>